

AdisInsight


Written by scientists

- A database for drug research and development, disease treatment and decision making, based on trusted, scientifically-sound data
- Expertly reviewed, assessed and summarized by a team of scientists
- A single search delivers results on drugs, trials, deals and safety

Giving you
insights

AdisInsight brings together essential scientific information on drugs in commercial development, key clinical trials, deals and safety profiles, in one easy-to-use database.

Welcome to AdisInsight



Whatever your involvement in the world of drug development, from a researcher to a strategist, a regulator to a healthcare provider, you will benefit from the greater perspective that AdisInsight provides.

Make better informed decisions

Gain a greater perspective of the drug landscape with a single search working across profiles of the drugs, clinical trials, deals, patents and adverse events shaping global drug research and future clinical practice.

Gain a competitive advantage

Stay at the forefront of your area by adapting your research focus according to the most compelling new information

Improve work efficiency

Reduce the time taken to answer critical questions with easily digestible, consolidated scientific and commercial data

Get timely access to expert narratives

Information is assessed and consolidated from multiple sources, so you can trust the content first time around

Align efforts to improve patient care

AdisInsight makes expertly-written drug information more accessible to everyone, no matter what your background, providing a shared knowledge base to help in translating research into practice



Adis are experts in drug evaluation with more than 40 years' experience of providing trusted, independent content

Expertly-written content from across the drug lifecycle

Drugs

Access leading, evidence-based scientific and market information on drugs in commercial development worldwide. Drug and cell-based products are tracked across all therapeutic areas and throughout the entire development process, from discovery to launch.

AdisInsight drug profiles include:

- Key development milestones
- Development status and history
- Drug properties
- Chemical synopses
- Pharmacokinetics data
- Pharmacodynamics data
- Company agreements
- Trial landscape and details
- Related safety reports
- Patent information
- Related drugs
- Drug limitations
- Immunogenicity

Trials

Quickly identify the key clinical trials being performed to advance these drugs through international regulatory pathways, with coverage of both international and observational trials. Profiles include:

- Phase of trial and current status
- Trial purpose, focus and design
- Primary and other endpoints
- Diseases and subjects treated
- Inclusion and exclusion criteria
- Trial identifiers
- Organizations involved
- Initiation, completion and end dates
- Interventions
- Study center and investigator details
- Trial history
- Outcomes and results
- Related authors

Deals

Review concise summaries of purchases and acquisitions, joint ventures, and agreements for licensing, R&D, development, manufacturing, distribution and marketing with deal values given, where available. AdisInsight can help you to keep up with the ever-changing landscape of drug development, to identify opportunities for investment, business development and collaboration, and benchmark relative deal values and terms for your own technologies.

Safety

The most comprehensive and reliable worldwide resource for pharmacovigilance literature monitoring, AdisInsight provides fast and easy access to published adverse drug reaction (ADR) case reports, drug safety studies and regulatory news covering all drugs and therapeutic areas, updated daily. Safety records provide:

- Easy identification of serious, overdose, interaction and first published case reports
- Expert summaries of Individual Case Safety Reports (ICSRs) that comply with CIOMS II guidelines for Periodic Safety Update Reports (PSURs)
- WHO contextual adverse event data for first published case reports
- Full citation details with links to the full-text where available, to support further research
- Reports dating back to 1982

Greater perspective leads to better decision making

AdisInsight connects the world of drug development by bringing together information from each stage of the drug lifecycle into a single database.

You can retrieve highly focused results with a single search, eliminating the need to access multiple databases.

In addition to being able to search across the whole database, content within profiles is also interlinked. For example, when reading a drug profile you can see the related trials and adverse events and link through to these related records.

By connecting this information, you can see the *big picture* of a drug or disease, providing a richer context to your research and decision making and helping you to make greater discoveries.

Highlighted Feature: Trial Landscapes

Within a drug profile you can see a full trial landscape by phase and indication, helping you to predict what the lead indication/s may be, and assess how seriously other indications are being pursued

The screenshot displays the AdisInsight interface with two main panels: **DRUGS** and **TRIALS**.

DRUGS Panel (Left):

- Drug Profile:** Ramipril. Alternative Names: Acuvi®, Altace®, Carase®, Delix®, HOE 498, Hypren®, Pramace®, Quark®, Ramace®, Triatec®, Tritace®, Unipril®, Vesdil®. Latest Information Update: 19 Mar 2015.
- At a glance:**
 - Originator: sanofi-aventis
 - Developer: AstraZeneca; King Pharmaceuticals; Monarch Pharmaceuticals; Pfizer; Sanofi
 - Class: Antihypertensives; Heart failure therapies; Heterocyclic bicyclo compounds; Small molecules
 - Mechanism of Action: ACE inhibitors
 - Orphan Drug Status: No
 - On Fast track: No
 - New Molecular Entity: Yes
 - Highest Development Phases: Marketed (Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension), Clinical Phase Unknown (Ischaemic heart disorders), Discontinued (Kidney disorders; Type 2 diabetes mellitus)
 - Most Recent Events: (Empty)
- Table of Contents:**
 - At a glance
 - Development Overview
 - Introduction
 - Company agreements
 - Key development milestones
 - Patent information
 - Drug Properties & Chemical Synopsis
 - Trial Landscape** (highlighted)
 - Development Status
 - Summary Table
 - Related Drugs
 - Commercial Information
 - Involved Organisations

TRIALS Panel (Right):

- Trial Profile:** A placebo-controlled, double-blind, randomized, multicenter study of ramipril 5 and 10 mg capsules and insulin infusion in subjects with unstable coronary syndromes. Completed. Phase of Trial: Phase III. Latest Information Update: 10 Jan 2011.
- At a glance:**
 - Drugs: Insulin; Ramipril
 - Indications: Acute coronary syndromes; Myocardial infarction
 - Focus: Therapeutic Use
 - Acronyms: FOCUS
 - Sponsors: Sanofi
- Trial Overview Table:**

Indication	Phase 0	Phase I	Phase II	Phase III	Phase IV
Acute coronary syndromes	-	-	-	1	-
Asthenozoospermia	-	-	1	-	-
Atherosclerosis	-	-	-	2	-
Atrial fibrillation	-	-	-	1	-
- Table of Contents:**
 - At a glance
 - Trial Overview
 - Comments
 - Primary Endpoints
 - Diseases Treated
 - Subjects
 - Trial Details
 - Identifiers
 - Organisations
 - Trial Dates
 - Other Details
 - Interventions
 - Trial Centres
 - Investigators
 - Centres
 - Trial History

What sets AdisInsight apart from other resources is our ...*scientific expertise*

Unlike our competitors, **we don't just "copy and paste" or add unnecessary information** in a bid to have the biggest database. Our focus is on **quality and relevance**, which is achieved by following a methodical approach to identifying, evaluating and summarizing content.



 Editorial Review

Monitoring

We continuously monitor a variety of global sources to identify **new data**.



Assessing

New data is reviewed and assessed to **extract relevant information**, based on its significance and scientific merit.

Categorizing



Detailed and consistent **indexing** is applied to support highly focused searching

Validating

Information is verified across multiple sources to **resolve discrepancies** and remove bias.

Expert Summaries

Concise narratives tell the story, using the **most compelling evidence**, and cutting out unnecessary noise.



Easy-to-use Platform

The simple search offers the fastest way to start exploring, with the most commonly used search criteria such as Drug Name, Mechanism of Action and Adverse Event, all available upfront.

Results are delivered across all content sets – drug profiles, clinical trials, safety reports and deals.

Intelligent search facets provide at-a-glance counts of results by key criteria and can be used to quickly refine your search

If you know exactly what you are looking for, you can build more detailed queries using the Advanced Search

Getting the answers you need from AdisInsight is simple, no matter how specific or broad your enquiry. The user-friendly platform is designed to help you find the information you need.

The screenshot displays the AdisInsight search results for the drug 'Exenatide'. The interface includes a search bar at the top with 'Exenatide' entered. Below the search bar, there are navigation links for 'Home' and 'Contact Us'. The main content area is divided into two sections: 'Refine Your Search' on the left and 'Search results for Drug Name: "Exenatide"' on the right. The 'Refine Your Search' section contains several facets: Indication (Diabetes mellitus: 14, Metabolic disorders: 14, Type 2 diabetes mellitus: 13, Obesity: 2, Parkinson's disease: 1), Phase (Marketed: 2, Registered: 2, Phase III: 3, Phase II/III: 1, Phase II: 6), Location (USA: 9, China: 5, European Union: 5, South Korea: 5, Germany: 4), and Mechanism Of Action (Glucagon-like peptide 1 receptor agonists: 13, Glucagon-like peptide 1 stimulants: 1, Insulinotropin agonists: 1). The 'Search results' section shows a summary of 15 Drugs, 181 Trials, 45 Safety Reports, and 9 Deals. It lists two results: 'Exenatide long-acting release - AstraZeneca' (11 Mar 2015) and 'Exenatide' (10 Mar 2015). Each result includes details on active and inactive indications, originator, and licensed by.

Start exploring the new AdisInsight today at adisinsight.springer.com

Email us at AskTheExpert.
AdisInsight@springer.com to
learn more about AdisInsight

Or request a trial at
[adisinsight.springer.com/
request-a-trial](http://adisinsight.springer.com/request-a-trial)

